- EPA (Eicosapentaenoic Acid) and DHA (Docosahexaenoic Acid) are essential omega-3 fatty acids widely used in nutritional supplements, pharmaceuticals, and functional food applications due to their well-documented benefits for heart, brain, and eye health
- The demand for EPA and DHA is significantly driven by the increasing prevalence of age-related chronic conditions, including cardiovascular disease, cognitive decline, and vision disorders, along with a growing preference for preventive healthcare
- North America is expected to dominate the global EPA and DHA market, accounting for 40% of the total market share in 2024. This dominance is driven by high awareness of health supplements, a growing elderly population, and the strong presence of key omega-3 product manufacturers in the region
- Asia-Pacific is anticipated to be the fastest-growing region in the EPA and DHA market, with a CAGR of 7.8% during the forecast period. The region's market share is expected to increase to 30% by 2032. This growth is driven by rising health consciousness, increasing disposable income, and growing demand for infant and maternal nutrition products
- The dietary supplements segment is expected to dominate the EPA and DHA market, holding a significant share of 45% in 2024. This growth is fueled by high consumer adoption for managing heart and brain health, alongside innovations in delivery formats such as soft gels, powders, and gummies
